Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
BioCryst pediatric Orladeyo PDUFA decision today could make it first oral HAE prophylaxis for children 2-11 with ±15% volatility expected, Isomorphic Labs (Google DeepMind spinout)
XBI gaps up 1.8% on cool CPI print (2.7% headline) cementing January Fed rate cut expectations, BioCryst pediatric Orladeyo PDUFA tomorrow could make it first
Pfizer commits $1.9B to YaoPharma oral GLP-1 filling pipeline gap post-danuglipron failure, Syndax validates Revuforj menin inhibitor with 23-26% complete response in KMT2Ar leukemia, Incyte’s
Wave Life Sciences soars 147% on first-in-human INHBE siRNA data showing 9.4% visceral fat reduction with muscle preservation, Structure Therapeutics doubles on oral GLP-1 achieving
SciNeuro secures $53M Series B for CNS pipeline, Capricor analysts initiate at $51-$60 after 371% surge, Intuitive falls 2.1% on Medtronic competition, ImPact achieves 70%
Capricor rockets 371% on Phase 3 DMD cell therapy success, Medtronic breaks Intuitive’s robotics monopoly, Bristol Myers delays Cobenfy yet rallies on relief, and bifurcated
Dr. Richard Pazdur retires creating oncology approval void, US-UK 0% pharma tariffs officially implemented, Regeneron commits $150M to Tessera gene writing, IQVIA partners with AWS
U.S.-UK eliminate medicine tariffs, Abbott acquires Exact Sciences for $21 billion, FDA signals stricter vaccine approvals, Otsuka wins accelerated kidney nod, and AI infrastructure gains
Zydus-RK Pharma license supportive care injectable, biomimetics market forecast to reach $73.6B by 2034, and Hong Kong approves IASO Bio’s CAR-T as device quality vigilance
FDA approves first gene-replacement therapy for SMA patients 2+ years as Abbott’s 3-million sensor correction exposes fundamental questions about CGM accuracy and post-market surveillance The
